Investment of $285m will create more than 250 new jobs
Genentech, a member of the Roche Group, is to invest more than US$285m in an expansion of its biologics manufacturing facilities in Vacaville and Oceanside, California.
The company’s US manufacturing network spans three locations in California – South San Francisco, Vacaville, and Oceanside – and Hillsboro, Oregon. When the expansion is complete, Genentech’s Vacaville facility will not only be the largest producer of biologic medicines for the Roche Group but also the largest biotech manufacturing facility in the world.
'This investment and expansion will result in the addition of more than 250 new jobs at the Vacaville and Oceanside facilities over the next four years, bringing the total number of Genentech manufacturing jobs in California to close to 3,000,' said Ian Clark, Chief Executive Officer of Genentech. 'California has always had an impressive skilled workforce that has allowed Genentech to hire diverse and talented individuals in various disciplines,' he added.